|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/04/21 Emmaus Life Sciences, Inc. 10-K 12/31/20 97:18M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.82M
2: EX-4.24 Instrument Defining the Rights of Security Holders HTML 65K
3: EX-4.25 Instrument Defining the Rights of Security Holders HTML 114K
4: EX-4.27 Instrument Defining the Rights of Security Holders HTML 114K
5: EX-10.37 Material Contract HTML 30K
6: EX-10.38 Material Contract HTML 33K
7: EX-23.1 Consent of Expert or Counsel HTML 24K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
10: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
17: R1 Document and Entity Information HTML 88K
18: R2 Consolidated Balance Sheets HTML 121K
19: R3 Consolidated Balance Sheets (Parenthetical) HTML 41K
20: R4 Consolidated Statements of Operations and HTML 113K
Comprehensive Income (Loss)
21: R5 Consolidated Statements of Changes in HTML 92K
Stockholders' Deficit
22: R6 Consolidated Statements of Cash Flows HTML 142K
23: R7 Description of Business HTML 33K
24: R8 Summary of Significant Accounting Policies HTML 67K
25: R9 Revenues HTML 117K
26: R10 Selected Financial Statement Captions - Assets HTML 82K
27: R11 Investments HTML 122K
28: R12 Selected Financial Statement Captions - HTML 101K
Liabilities
29: R13 Notes Payable HTML 508K
30: R14 Stockholders' Deficit HTML 394K
31: R15 Income Taxes HTML 139K
32: R16 Leases HTML 46K
33: R17 Commitments and Contingencies HTML 29K
34: R18 Related Party Transactions HTML 391K
35: R19 Defined Contribution Plan HTML 27K
36: R20 Subsequent Events HTML 36K
37: R21 Summary of Significant Accounting Policies HTML 133K
(Policies)
38: R22 Revenues (Tables) HTML 117K
39: R23 Selected Financial Statement Captions - Assets HTML 87K
(Tables)
40: R24 Investments (Tables) HTML 114K
41: R25 Selected Financial Statement Captions - HTML 101K
Liabilities (Tables)
42: R26 Notes Payable (Tables) HTML 574K
43: R27 Stockholders' Deficit (Tables) HTML 412K
44: R28 Income Taxes (Tables) HTML 139K
45: R29 Leases (Tables) HTML 43K
46: R30 Related Party Transactions (Tables) HTML 388K
47: R31 Subsequent Events (Tables) HTML 33K
48: R32 Description of Business (Details Narrative) HTML 43K
49: R33 Summary of Significant Accounting Policies HTML 85K
(Details Narrative)
50: R34 Revenues (Details) HTML 34K
51: R35 Revenues (Details 1) HTML 43K
52: R36 Revenues (Details 2) HTML 33K
53: R37 Revenues (Details Narrative) HTML 41K
54: R38 Selected Financial Statement Captions - Assets HTML 35K
(Details)
55: R39 Selected Financial Statement Captions - Assets HTML 32K
(Details 1)
56: R40 Selected Financial Statement Captions - Assets HTML 39K
(Details 2)
57: R41 Selected Financial Statement Captions - Assets HTML 26K
(Details Narrative)
58: R42 Investments (Details Narrative) HTML 97K
59: R43 Investments (Details) HTML 32K
60: R44 Investments (Details 1) HTML 55K
61: R45 Investments (Details 2) HTML 70K
62: R46 Selected Financial Statement Captions - HTML 59K
Liabilities (Details)
63: R47 Selected Financial Statement Captions - HTML 32K
Liabilities (Details 1)
64: R48 Selected Financial Statement Captions - HTML 35K
Liabilities (Details Narrative)
65: R49 Notes Payable (Details) HTML 83K
66: R50 Notes Payable (Details 1) HTML 61K
67: R51 Notes Payable (Details 2) HTML 62K
68: R52 Notes Payable (Details Narrative) HTML 65K
69: R53 Notes Payable (Details 3) HTML 35K
70: R54 Notes Payable (Details 4) HTML 37K
71: R55 Notes Payable (Details 5) HTML 47K
72: R56 Stockholders' Deficit (Details Narrative) HTML 180K
73: R57 Stockholders' Deficit (Details) HTML 32K
74: R58 Stockholders' Deficit (Details 1) HTML 41K
75: R59 Stockholders' Deficit (Details 2) HTML 34K
76: R60 Stockholders' Deficit (Details 3) HTML 44K
77: R61 Stockholders' Deficit (Details 4) HTML 36K
78: R62 Stockholders' Deficit (Details 5) HTML 78K
79: R63 Stockholders' Deficit (Details 6) HTML 49K
80: R64 Stockholders' Deficit (Details 7) HTML 54K
81: R65 Income Taxes (Details) HTML 35K
82: R66 Income Taxes (Details 1) HTML 51K
83: R67 Income Taxes (Details 2) HTML 34K
84: R68 Income Taxes (Details Narrative) HTML 41K
85: R69 Income Taxes (Details 3) HTML 42K
86: R70 Leases (Details Narrative) HTML 62K
87: R71 Leases (Details) HTML 41K
88: R72 Commitments and Contingencies (Details Narrative) HTML 41K
89: R73 Related Party Transactions (Details) HTML 143K
90: R74 Related Party Transactions (Details Narrative) HTML 38K
91: R75 Defined Contribution Plan (Details Narrative) HTML 35K
92: R76 Subsequent Events (Details) HTML 35K
93: R77 Subsequent Events (Details Narrative) HTML 64K
95: XML IDEA XML File -- Filing Summary XML 177K
16: XML XBRL Instance -- emma-10k_20201231_htm XML 5.05M
94: EXCEL IDEA Workbook of Financial Reports XLSX 131K
12: EX-101.CAL XBRL Calculations -- emma-20201231_cal XML 239K
13: EX-101.DEF XBRL Definitions -- emma-20201231_def XML 1.01M
14: EX-101.LAB XBRL Labels -- emma-20201231_lab XML 1.79M
15: EX-101.PRE XBRL Presentations -- emma-20201231_pre XML 1.48M
11: EX-101.SCH XBRL Schema -- emma-20201231 XSD 260K
96: JSON XBRL Instance as JSON Data -- MetaLinks 484± 742K
97: ZIP XBRL Zipped Folder -- 0001564590-21-022930-xbrl Zip 522K
Exhibit 31.1
Certification of Chief Executive Officer pursuant to Item 601(b)(31) of Regulation S‑K,
as adopted pursuant to Section 302 of the Sarbanes‑Oxley Act of 2002
I, Yutaka Niihara, certify that:
|
1. |
I have reviewed this annual report of Emmaus Life Sciences, Inc.; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a‑15(f) and 15d‑15(f)) for the registrant and have: |
|
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
(b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
(c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
(d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|
/s/ Yutaka Niihara |
|
Chief Executive Officer |
|
(Principal Executive Officer) |
|
Date: May 3, 2021 |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 5/4/21 | |||
| Filed on: | 5/3/21 | |||
| For Period end: | 12/31/20 | 10-K/A, NT 10-K | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/23 Emmaus Life Sciences, Inc. 10-K 12/31/22 88:18M Donnelley … Solutions/FA 3/31/22 Emmaus Life Sciences, Inc. 10-K 12/31/21 98:18M ActiveDisclosure/FA 8/26/21 Emmaus Life Sciences, Inc. 10-Q 6/30/20 89:21M ActiveDisclosure/FA 8/26/21 Emmaus Life Sciences, Inc. 10-Q 9/30/20 83:15M ActiveDisclosure/FA 8/26/21 Emmaus Life Sciences, Inc. 10-Q 3/31/20 84:18M ActiveDisclosure/FA 8/10/21 Emmaus Life Sciences, Inc. 10-K/A 12/31/20 92:18M ActiveDisclosure/FA |